The project focuses on a better understanding of the fact that risk factors may be associated with changes in epigenetic alterations, especially DNA methylation, and these changes may be associated with other alterations at the genomic level (mRNA and miRNA) or proteomics. We intend to develop and validate a new therapeutic model, which is based on evaluating the effect of a chemical compound on several normal and tumour breast cancer cell lines. In order to be able to identify the key dose that turned a carcinogenic compound into a therapeutic compound, other therapeutic agents such as p53siRNA and EGCG will be associated.